News | August 19, 2014

Class 1 Recall Initiated for Diamondback 360 Peripheral Orbital Atherectomy System

Cardiovascular Systems said sheath may fracture during use

Cardiovascular Systems is recalling certain lots of the Diamondback 360 Peripheral Orbital Atherectomy System, because they may contain defective saline sheaths that could fracture during use. If this happens, fragments of the sheath could possibly block blood vessels. The U.S. Food and Drug Administration (FDA) said as of this week, there are no reports of patient injuries to date.
 
The model number for the system in DPB-125MICRO145 (Part number 7-10003). The affected lot numbers include: 100573, 100575, 100674, 100676, 100678 and 100680. The vendor said 94 affected devices were manufactured from May 8, 2014 to May 9, 2014, and 48 were distributed from May 16, 2014 to May 20, 2014.
 
The Diamondback 360 Peripheral Orbital Atherectomy System is a high-speed cutting tool inserted via a catheter through the skin into a patient’s blood vessel. The system is used to reestablish blood flow in narrowed arteries or arterio-venous dialysis shunts.
 
Cardiovascular Systems sent an “Urgent Medical Device Recall” letter to their customers May 27. The letter identified the problem and the specific products affected by the recall. The letter advises customers to:
Remove affected devices from service.
Complete and return a “Customer Acknowledgement Form.”
Return affected devices to Cardiovascular Systems
For more information, contact Cardiovascular Systems Customer Service at 877.274.0901.
 
For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm410527.htm
 

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init